Dana-Farber’s Breast Oncology Center posted on X, about recent paper by Kevin Kalinsky et al., titled “Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial“ published on Journal of Clinical Oncology.
Authors: Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Stephanie L. Graff, Kyong Hwa Park, Rinath Jeselsohn, Umut Demirci, Miguel Martin, Rachel M. Layman, Sara A. Hurvitz, Sarah Sammons, Peter A. Kaufman, Montserrat Muñoz, Jiun-I Lai, Holly Knoderer, Cynthia Sandoval, Aarti R. Chawla, Bastien Nguyen, Yanhong Zhou, Elizabeth Ravenberg, Lacey M. Litchfield, Lillian Smyth, Seth A. Wander.
“New at Journal of Clinical Oncology. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial.“